Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2007

View Archived Issues

New data on oblimersen pharmacokinetics, in vivo activity reported

New agents for treating neurological disorders disclosed in recent patents

Pharmacokinetics, pharmacodynamics of fospropofol studied

CNTNAP2 may be a candidate gene for autism

Nereus Pharmaceuticals' NPI-0052, NPI-2358 assessed in phase I cancer studies

Oxaliplatin formulation MBP-426 well tolerated in phase I study

Celtic Pharma completes enrollment in phase IIb TA-NIC study

Coley and Pfizer nominate second TLR9 agonist for clinical development

N30 Pharma enters S-nitrosothiol license agreement with NitroMed

Ipsen and Debiopharm extend their commercialization agreement for Decapeptyl

Gene Logic changes name to Ore Pharmaceuticals and sells genomics assets

Organon enters license agreement with Endotis for antithrombotic compounds

Apthera completes end of phase II meeting with FDA for NeuVax for breast cancer

Novo Nordisk licenses ghrelin antagonist program to Sapphire for treatment of obesity

ArQule initiates two phase II trials of ARQ-197

MAP initiates phase IIa clinical trial of MAP-0005 for asthma

Merck Serono signs agreement with the Ecole Polytechnique Federale de Lausanne

Nycomed signs partnership agreement with NPS to develop and commercialize Gattex

MedImmune and Seattle Genetics further their antibody-drug conjugate collaboration

Collegium successfully completes proof-of-concept study for oral oxycodone COL-003

FibroGen reports novel HIF prolyl hydroxylase inhibitors in a recent patent

Recent patents describe new treatment options for diabetes and associated disorders

Toll-like receptor 3 may be involved in the pathogenesis of Alzheimer's disease

GSK launches Atriance for treatment of lymph cancer

Novartis launches Exelon transdermal patch for treatment of Alzheimer's dementia

Bayer temporarily suspends worldwide marketing of Trasylol

Selective muscarinic agonists with potential for neurological disorders presented at SfN

Choline derivative a potential candidate for neurodegenerative and cognition disorders

Selective nAChR allosteric modulator safe and effective in improving cognition in rodents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...